Terms: = Pancreatic cancer AND FANCD2, FANCD, 2177, ENSG00000144554, FLJ23826, FAD, FACD, FA4, FA-D2, FAD2, DKFZp762A223 AND Treatment
10 results:
1. Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells.
Kopecka J; Barbanente A; Vitone D; Arnesano F; Margiotta N; Berchialla P; Niso M; Riganti C; Abate C
Pharmacol Rep; 2023 Dec; 75(6):1588-1596. PubMed ID: 37796435
[TBL] [Abstract] [Full Text] [Related]
2. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
Li B; Li Y; Zhou H; Xu Y; Cao Y; Cheng C; Peng J; Li H; Zhang L; Su K; Xu Z; Hu Y; Lu J; Lu Y; Qian L; Wang Y; Zhang Y; Liu Q; Xie Y; Guo S; Mehal WZ; Yu D
Hepatology; 2024 Feb; 79(2):289-306. PubMed ID: 37540187
[TBL] [Abstract] [Full Text] [Related]
3. Preomic profile of BxPC-3 cells after treatment with BRC4.
Previtali V; Myers SH; Poppi L; Wynne K; Casamassima I; Girotto S; Di Stefano G; Farabegoli F; Roberti M; Oliviero G; Cavalli A
J Proteomics; 2023 Sep; 288():104983. PubMed ID: 37536521
[TBL] [Abstract] [Full Text] [Related]
4. Role of the ERO1-PDI interaction in oxidative protein folding and disease.
Shergalis AG; Hu S; Bankhead A; Neamati N
Pharmacol Ther; 2020 Jun; 210():107525. PubMed ID: 32201313
[TBL] [Abstract] [Full Text] [Related]
5. [Stereotactic body radiotherapy: Passing fad or revolution?].
Vallard A; Vial N; Jmour O; Rehailia-Blanchard A; Trone JC; Sotton S; Daguenet E; Guy JB; Magné N
Bull Cancer; 2020 Feb; 107(2):244-253. PubMed ID: 31864665
[TBL] [Abstract] [Full Text] [Related]
6. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract] [Full Text] [Related]
7. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.
Morse DL; Balagurunathan Y; Hostetter G; Trissal M; Tafreshi NK; Burke N; Lloyd M; Enkemann S; Coppola D; Hruby VJ; Gillies RJ; Han H
Biochem Pharmacol; 2010 Sep; 80(5):748-54. PubMed ID: 20510208
[TBL] [Abstract] [Full Text] [Related]
8. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
[TBL] [Abstract] [Full Text] [Related]
9. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract] [Full Text] [Related]
10. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
[TBL] [Abstract] [Full Text] [Related]
